MCID: IND005
MIFTS: 20

Indolent B Cell Lymphoma

Categories: Immune diseases, Rare diseases

Aliases & Classifications for Indolent B Cell Lymphoma

MalaCards integrated aliases for Indolent B Cell Lymphoma:

Name: Indolent B Cell Lymphoma 52
B Cell Lymphoma, Indolent 52

Classifications:



Summaries for Indolent B Cell Lymphoma

MalaCards based summary : Indolent B Cell Lymphoma, also known as b cell lymphoma, indolent, is related to b-cell lymphoma and lymphoma. The drugs rituximab and Lenalidomide have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone.

Related Diseases for Indolent B Cell Lymphoma

Diseases related to Indolent B Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 46, show less)
# Related Disease Score Top Affiliating Genes
1 b-cell lymphoma 10.8
2 lymphoma 10.8
3 follicular lymphoma 10.5
4 marginal zone b-cell lymphoma 10.5
5 leukemia, chronic lymphocytic 10.4
6 mantle cell lymphoma 10.4
7 neutropenia 10.4
8 lymphoma, hodgkin, classic 10.3
9 lymphoma, non-hodgkin, familial 10.3
10 indolent b-cell non-hodgkin lymphoma 10.3
11 diffuse large b-cell lymphoma 10.3
12 lymphoplasmacytic lymphoma 10.3
13 exanthem 10.2
14 splenic marginal zone lymphoma 10.2
15 macroglobulinemia 10.2
16 b-cell non-hodgkin lymphoma 10.2
17 hairy cell leukemia 10.1
18 burkitt lymphoma 10.0
19 cryoglobulinemia, familial mixed 10.0
20 myelodysplastic syndrome 10.0
21 graft-versus-host disease 10.0
22 t-cell lymphoma, subcutaneous panniculitis-like 10.0
23 peripheral t-cell lymphoma 10.0
24 aphasia 10.0
25 cutaneous t cell lymphoma 10.0
26 lymphoproliferative syndrome 10.0
27 waldenstroem's macroglobulinemia 10.0
28 nodal marginal zone lymphoma 10.0
29 diarrhea 10.0
30 thrombocytopenia 10.0
31 hepatitis c 10.0
32 hepatitis b 10.0
33 cryoglobulinemia 10.0
34 cll/sll 10.0
35 lung lymphoma 10.0
36 mature b-cell neoplasm 10.0
37 pemphigus 10.0
38 alopecia 10.0
39 splenomegaly 10.0
40 indolent primary cutaneous b-cell lymphoma 10.0
41 primary pulmonary lymphoma 10.0
42 splenic diffuse red pulp small b-cell lymphoma 10.0
43 paraneoplastic pemphigus 10.0
44 histiocytic sarcoma 10.0
45 nodal marginal zone b-cell lymphoma 10.0
46 type ii mixed cryoglobulinemia 10.0

Graphical network of the top 20 diseases related to Indolent B Cell Lymphoma:



Diseases related to Indolent B Cell Lymphoma

Symptoms & Phenotypes for Indolent B Cell Lymphoma

Drugs & Therapeutics for Indolent B Cell Lymphoma

Drugs for Indolent B Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 31, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 3 174722-31-7 10201696
2
Lenalidomide Approved Phase 3 191732-72-6 216326
3 Immunologic Factors Phase 3
4 Antirheumatic Agents Phase 3
5 Antineoplastic Agents, Immunological Phase 3
6 Angiogenesis Inhibitors Phase 3
7
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
8
ofatumumab Approved Phase 2 679818-59-8 6918251
9
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
10
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
11
Oxaliplatin Approved, Investigational Phase 1, Phase 2 61825-94-3 43805 6857599 5310940 9887054
12
Velpatasvir Approved, Investigational Phase 2 1377049-84-7 67683363
13
Ledipasvir Approved Phase 2 1256388-51-8 67505836
14
Sofosbuvir Approved Phase 2 1190307-88-0 45375808
15
Ixazomib Approved, Investigational Phase 1, Phase 2 1072833-77-2
16 Molgramostim Investigational Phase 2 99283-10-0
17 Immunoglobulins, Intravenous Phase 2
18 Vaccines Phase 2
19 Keyhole-limpet hemocyanin Phase 2
20 Adjuvants, Immunologic Phase 2
21 Immunoglobulin Idiotypes Phase 2
22 Antimetabolites Phase 1, Phase 2
23 Hu5F9-G4 Phase 1, Phase 2
24 Ledipasvir, sofosbuvir drug combination Phase 2
25
protease inhibitors Phase 1, Phase 2
26 HIV Protease Inhibitors Phase 1, Phase 2
27
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
28 Pharmaceutical Solutions Phase 1
29 Bendamustine Hydrochloride Phase 1
30
Decitabine Approved, Investigational Early Phase 1 2353-33-5 451668
31 Tetrahydrouridine Investigational Early Phase 1 18771-50-1

Interventional clinical trials:

(showing 28, show less)
# Name Status NCT ID Phase Drugs
1 A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT). Recruiting NCT02390869 Phase 3 R2-MANT;R-MANT
2 Phase II Trial of Maintenance Rituximab Plus FavId® and GM-CSF Immunotherapy in Patients With Treatment-Naive Indolent B-Cell Lymphoma Unknown status NCT00258336 Phase 2
3 A Phase 2 Study of VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma Completed NCT00085696 Phase 2 VELCADE and rituximab
4 A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas Completed NCT00542919 Phase 2 enzastaurin
5 Phase II Trial Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma Completed NCT01239394 Phase 2 ofatumumab
6 A Phase II Trial to Evaluate the Rate of Immune Response Using Idiotype Immunotherapies Produced by Molecular Biological Means for Treatment of Indolent B Cell Lymphoma Completed NCT00004198 Phase 2
7 A Phase II Study of VELCADE With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma Completed NCT00093769 Phase 2 bortezomib + rituximab
8 Safety and Activity of Rituximab(HLX01) in Combination With Pegylated Interferon α-2b in Patients With Newly Diagnosed Advanced Indolent B-cell Lymphoma: a Single-arm, Multicenter, Phase 2 Study Recruiting NCT04246359 Phase 2 Rituximab Biosimilar;Pegylated Interferon α-2b
9 Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma Recruiting NCT02494700 Phase 2 Orbital Radiation
10 A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Recruiting NCT02953509 Phase 1, Phase 2 Hu5F9-G4;Rituximab;Gemcitabine Hydrochloride;Oxaliplatin
11 A Cancer Research UK Phase I/IIa Clinical Trial of BI-1206; an Antibody to FcƔRIIB (CD32b), as a Single Agent and in Combination With an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Malignancy Recruiting NCT02933320 Phase 1, Phase 2
12 A Multicenter Study to Evaluate the Anti-viral Activity of an Interferon-free Treatment With Ledipasvir/Sofosbuvir (G1 and G4) and Sofosbuvir/Velpatasvir (G2 and G3) for Patients With Hepatitis C Virus-associated Indolent B-cell Lymphomas Active, not recruiting NCT02836925 Phase 2 Ledipasvir+Sofosbuvir;Sofosbuvir+Velpatasvir
13 A Phase IB/II Trial of Lenalidomide (Revlimid®), Ixazomib and Rituximab (RIXAR) as Front-line Therapy for High Risk Indolent B Cell Lymphoma Active, not recruiting NCT02898259 Phase 1, Phase 2 Ixazomib;Lenalidomide;Rituximab
14 A Phase 1/2 Study of ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With Rituximab Active, not recruiting NCT02384954 Phase 1, Phase 2
15 A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 Active, not recruiting NCT00466531 Phase 1, Phase 2 cyclophosphamide
16 Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia Terminated NCT01944943 Phase 2 Vismodegib
17 Multicenter Phase II Study for Zevalin® in Patients With Relapsed/Refractory Indolent Lymphomas: Extranodal Marginal Lymphoma of MALT Type, Nodal Marginal Zone B-Cell Lymphoma, and Splenic Marginal B-Cell Lymphoma Terminated NCT00493454 Phase 2 Zevalin;Rituximab;^111 In Ibritumomab Tiuxetan
18 Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Previously Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Withdrawn NCT00414089 Phase 2 90Y-ibritumomab tiuxetan (Zevalin)
19 Rituximab Anti-CD20 Monoclonal Antibody Plus Oral Cyclophosphamide as Initial Treatment of Indolent Lymphoma Withdrawn NCT00003605 Phase 2 cyclophosphamide
20 Phase II Trials of CHOP Chemotherapy and Interferon Alpha or Rituximab Anti-CD20 Monoclonal Antibody as Initial Treatment of Patients With Stage III and IV High-Risk Indolent B-Cell Lymphoma and Intermediate Grade B-Cell Lymphoma Withdrawn NCT00004039 Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
21 Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma Completed NCT00963274 Phase 1 Bortezomib;Romidepsin
22 A Phase 1 Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma Completed NCT01317901 Phase 1 TRU-016;Bendamustine;Rituximab
23 A Cancer Research UK Phase I Trial of the Anti-CD19 DI-B4 Monoclonal Antibody Given Intravenously, Weekly for Four Weeks, in Patients With Advanced CD19 Positive Indolent B-cell Malignancies Completed NCT01805375 Phase 1 DI-B4
24 The Role of Conformal External Beam Radiotherapy in the Management of Patients With Bulky Disease Undergoing Y90-Ibritumomab Tiuxetan (Zevalin) Radio-immunotherapy for Indolent B-cell Non-Hodgkin's Lymphoma Completed NCT00271050 Phase 1
25 BrUOG 326: A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With Bendamustine and Rituximab (BRiM) in Indolent Non-Hodgkin Lymphoma Recruiting NCT02257242 Phase 1 Rituximab;Bendamustine;Vincristine sulfate liposome injection
26 A Phase I Study of BKM120 and Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma Active, not recruiting NCT02049541 Phase 1 PI3K inhibitor BKM120
27 Vaccination of Lymphoma Patients With Dendritic Cell-lymphoma Cell Hybrids and Dendritic Cells Pulsed With Tumor Lysates Completed NCT00937183
28 p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies Completed NCT02846935 Early Phase 1 Decitabine;Tetrahydrouridine

Search NIH Clinical Center for Indolent B Cell Lymphoma

Genetic Tests for Indolent B Cell Lymphoma

Anatomical Context for Indolent B Cell Lymphoma

MalaCards organs/tissues related to Indolent B Cell Lymphoma:

40
B Cells, T Cells, Bone, Bone Marrow, Spleen, Spinal Cord, Lung

Publications for Indolent B Cell Lymphoma

Articles related to Indolent B Cell Lymphoma:

(showing 151, show less)
# Title Authors PMID Year
1
Impact of prednisolone dosage in the CHOP regimen for follicular lymphoma: a retrospective study. 61
32529585 2020
2
Rare lymphomas in routine practice-Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms. 61
32383192 2020
3
Safe administration of rituximab for follicular lymphoma after obinutuzumab infusion-related reaction. 61
31848991 2020
4
Light Chain Crystal Podocytopathy in a Patient With Systemic Indolent B-Cell Lymphoma. 61
32154460 2020
5
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. 61
31868245 2019
6
Clonal evolution of chronic lymphocytic leukemia to Langerhans cell histiocytosis: a case report. 61
31317311 2019
7
68Ga-Pentixafor PET/CT for Imaging of Chemokine Receptor 4 Expression in Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT. 61
31101745 2019
8
Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. 61
31849108 2019
9
Reproducing indolent B-cell lymphoma transformation with T-cell immunosuppression in LMP1/CD40-expressing mice. 61
30635651 2019
10
[Waldenström macroglobulinemia. Experience in 31 patients]. 61
31344163 2019
11
Multimodality imaging of indolent B cell lymphoma from diagnosis to transformation: what every radiologist should know. 61
30796644 2019
12
[Chronic Lymphocytic Leukemia]. 61
32157962 2019
13
Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma. 61
30906531 2019
14
Multiple cystic lung lesions and autoimmune thrombocytopaenia developing after chemotherapy for pulmonary indolent B-cell lymphoma with plasmacytic differentiation. 61
30567252 2018
15
Rare concurrent indolent B-cell lymphoma and plasmablastic transformation of myeloma. 61
30305474 2018
16
Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. 61
30389034 2018
17
90 Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experience. 61
29993147 2018
18
Copanlisib monotherapy activity in relapsed or refractory indolent B-cell lymphoma: Combined analysis from phase I and II studies. 61
32136862 2018
19
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia. 61
30190023 2018
20
Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond. 61
30190015 2018
21
The Bone Marrow Microenvironment in Waldenström Macroglobulinemia. 61
30190017 2018
22
Radioimmunotherapy of solid tumors: Approaches on the verge of clinical application. 61
29524233 2018
23
Cultured Cells Isolated from CNS Indolent B-Cell Lymphoma Have Characteristics of Mesenchymal Stem Cells: A Clinical Case and Scientific Research. 61
30595817 2018
24
Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent. 61
29963517 2018
25
Surgical management of splenic marginal zone lymphoma. 61
29043543 2018
26
From genetics to the clinic: a translational perspective on follicular lymphoma. 61
29422597 2018
27
Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance. 61
29168251 2018
28
Primary spinal mucosa-associated lymphoid tissue lymphoma: A case report. 61
29369169 2018
29
Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion. 61
30402490 2018
30
Pathways towards indolent B-cell lymphoma - Etiology and therapeutic strategies. 61
28802906 2017
31
Sites of extranodal involvement are prognostic in patients with stage 1 follicular lymphoma. 61
29108238 2017
32
Indolent B-Cell Lymphoid Malignancy in the Spleen of a Man Who Handled Benzene: Splenic Marginal Zone Lymphoma. 61
28951809 2017
33
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. 61
28103725 2017
34
Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report. 61
26970573 2017
35
Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma. 61
28055107 2017
36
Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review. 61
29387498 2017
37
Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). 61
27351685 2016
38
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma. 61
27784957 2016
39
Is rituximab sub-optimally dosed in indolent B cell lymphoma? 61
27136331 2016
40
An 84-Year-Old Woman With an Indolent B-Cell Lymphoma. 61
27535668 2016
41
The role of stem cell transplantation in Waldenstrom's macroglobulinemia. 61
27825469 2016
42
Introduction to a review series: the paradox of indolent B-cell lymphoma. 61
26989203 2016
43
The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma. 61
26989206 2016
44
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. 61
26423796 2016
45
Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-intense chemotherapy in dogs with advanced indolent B-cell lymphoma. 61
26296495 2015
46
Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group. 61
26275804 2015
47
Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors. 61
25808792 2015
48
Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. 61
26687959 2015
49
Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma. 61
25744235 2015
50
[Composite lymphoma: Simultaneous development of three different lymphomas in a single patient: A clinical case]. 61
26390733 2015
51
Intravascular large B-cell lymphoma secondary to lymphoplasmacytic lymphoma: a case report and review of literature with clonality analysis. 61
26045864 2015
52
Ibrutinib in B lymphoid malignancies. 61
26165513 2015
53
High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era. 61
24432894 2014
54
Survival of patients with transformed lymphoma in the rituximab era. 61
24414374 2014
55
[Case report: unusual clinical presentation of a follicular lymphoma]. 61
24772807 2014
56
[The progress in treatment for malignant lymphomas and the future direction]. 61
24724394 2014
57
C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas. 61
25337204 2014
58
Indolent B-cell lymphoma: the current standard in 2014. 61
24942940 2014
59
Paraneoplastic pemphigus occurs most commonly in indolent B cell lymphoma. 61
24481059 2014
60
Clinical characteristics and outcome in dogs with splenic marginal zone lymphoma. 61
23734665 2013
61
Renal small B-cell lymphoma with plasmacytic differentiation presenting with monoclonal gammopathy and disseminated intravascular coagulation syndrome. 61
31528616 2013
62
XIII. Waldenström's macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features. 61
23775655 2013
63
Clostridium septicum gas gangrene in the orbit: a case report. 61
23203898 2013
64
Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment? 61
24319212 2013
65
Atrazine and nitrate in public drinking water supplies and non-hodgkin lymphoma in nebraska, USA. 61
23515852 2013
66
Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma. 61
23121670 2012
67
Comparison on therapeutic effects of RFT and RCTVP regimen in the treatment of patients with indolent B-cell lymphoma in China. 61
22430608 2012
68
Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma. 61
23072591 2012
69
Marginal zone lymphoma: old, new, targeted, and epigenetic therapies. 61
23616915 2012
70
Radioimmunotherapy for B-cell non-hodgkin lymphomas. 61
22710895 2012
71
Primary thyroid lymphoma: the 40 year experience of a UK lymphoma treatment centre. 61
22367111 2012
72
[How to improve the efficacy of R-CHOP for indolent B-cell lymphoma?]. 61
22790636 2012
73
Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. 61
22083514 2012
74
A phase II study of rituximab combined with pirarubicin-cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma. 61
21827339 2012
75
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. 61
22045986 2012
76
Stromal cell contribution to human follicular lymphoma pathogenesis. 61
22973275 2012
77
A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma. 61
21831743 2011
78
Candidate genes contributing to the aggressive phenotype of mantle cell lymphoma. 61
21145576 2011
79
Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. 61
21931035 2011
80
BCL6 gene rearrangement and protein expression are associated with large cell presentation of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. 61
20830719 2011
81
Pathology, pathogenesis and molecular genetics of follicular NHL. 61
21658611 2011
82
Regression of indolent B-cell lymphoma after Lamivudine prophylaxis of hepatitis B virus infection. 61
21482990 2011
83
Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. 61
21270444 2011
84
Sequential development of histiocytic sarcoma and diffuse large b-cell lymphoma in a patient with a remote history of follicular lymphoma with genotypic evidence of a clonal relationship: a divergent (bilineal) neoplastic transformation of an indolent B-cell lymphoma in a single individual. 61
21317718 2011
85
Long-term treatment with rituximab of autoimmune autonomic ganglionopathy in a patient with lymphoma. 61
21059985 2011
86
Novel M-component based biomarkers in Waldenström's macroglobulinemia. 61
21454223 2011
87
Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma. 61
21045197 2011
88
Partial nodal involvement by marginal zone lymphoma. Use of IGK gene rearrangement analysis in diagnostic work-up. 61
21837920 2011
89
Atypical cytogenetics in therapy-related myelodysplastic syndrome secondary to indolent B-cell lymphoma. 61
21905579 2011
90
Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. 61
20884630 2010
91
Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas. 61
20631501 2010
92
Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. 61
20350661 2010
93
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. 61
19890959 2010
94
Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. 61
19965689 2010
95
Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia. 61
20054443 2009
96
Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study. 61
19907111 2009
97
Characterization of antibodies directed against the immunoglobulin light kappa chain variable chain region (VK) of hepatitis C virus-related type-II mixed cryoglobulinemia and B-cell proliferations. 61
19758144 2009
98
High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. 61
19474116 2009
99
Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. 61
19432900 2009
100
Characterization of the lymphoid stroma in Warthin's tumor of salivary gland by immunohistochemistry, heavy chain gene and Bcl-2 gene rearrangement. 61
19956447 2009
101
Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. 61
19150940 2009
102
Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. 61
19074729 2009
103
Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. 61
19018755 2009
104
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. 61
18809757 2009
105
Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma. 61
18950459 2008
106
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. 61
18509084 2008
107
Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. 61
18422781 2008
108
[Assessment for the image interpretation of 111In-ibritumomab tiuxetan in the phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma]. 61
19591405 2008
109
Nodular lymphocyte-predominant hodgkin lymphoma or T-cell/histiocyte rich large B-cell lymphoma: the problem in "grey zone" lymphomas. 61
18784812 2008
110
Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study. 61
17472971 2007
111
Association between lymphoma and melanoma: report of a single-center series of eight patients and a review of the literature. 61
16840192 2006
112
Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. 61
16630123 2006
113
[Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases]. 61
16613687 2006
114
Review of clinical radioimmunotherapy. 61
16503861 2006
115
Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma. 61
16367911 2005
116
Mucosa-associated lymphoid tissue lymphoma of the lacrimal gland--a case report. 61
16277031 2005
117
An unusual case of indolent B-cell lymphoma with distinct chronic lymphocytic leukemia and marginal zone differentiation according to the site of involvement. 61
16109617 2005
118
Extranodal marginal zone lymphoma: a case report and review of the literature. 61
16252536 2005
119
Positive troponin T without cardiac involvement in inclusion body myositis. 61
16112010 2005
120
Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma. 61
15958485 2005
121
Primary cutaneous B-cell lymphomas. Current concepts. I. 61
15531459 2004
122
Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study. 61
15540903 2004
123
Clonally related splenic marginal zone lymphoma and Hodgkin lymphoma with unmutated V gene rearrangements and a 15-yr time gap between diagnoses. 61
15287919 2004
124
T(11;18)-bearing pulmonary mucosa-associated lymphoid tissue lymphoma responding to cladribine. 61
15293572 2004
125
Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. 61
14695237 2004
126
Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. 61
15084620 2004
127
[Nodular lymphocyte predominance Hodgkin's disease and its differential diagnosis]. 61
15220833 2004
128
Hematological neoplasms with first presentation as spinal cord compression syndromes: a 10-year retrospective series and review of the literature. 61
14672506 2003
129
Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. 61
14531908 2003
130
An indolent B-cell lymphoma with t(2;8)(p12;q24) abnormality and absence of C-MYC amplification and TP53 deletion. A new variant? 61
12810261 2003
131
Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. 61
12573351 2003
132
[Cladribine]. 61
12610885 2003
133
[Experience with fludarabine treatment and review of the literature]. 61
12138643 2002
134
Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. 61
12123339 2002
135
[Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody]. 61
11904960 2002
136
[Development of monoclonal antibody therapy for malignant lymphoma]. 61
11904966 2002
137
Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection. 61
11920507 2002
138
[Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab)]. 61
11808346 2002
139
Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmacytic lymphoma. 61
11911426 2001
140
Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. 61
11389012 2001
141
[Treatment strategy for indolent B-cell lymphoma]. 61
11400299 2001
142
Cyclin D3 expression in non-Hodgkin lymphoma. Correlation with other cell cycle regulators and clinical features. 61
11242797 2001
143
Re-treatment of relapsed indolent B-cell lymphoma with rituximab. 61
11372734 2001
144
[New combination therapies in hematological malignancies]. 61
10740632 2000
145
Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. 61
10643704 2000
146
Rituximab in indolent lymphoma: the single-agent pivotal trial. 61
10561022 1999
147
CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. 61
10561023 1999
148
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. 61
10458242 1999
149
Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors. 61
9798678 1998
150
["Indolent B-cell lymphoma" based on the histologic review according to REAL classification]. 61
9597889 1998
151
The role of interferon in the therapy of malignant lymphoma. 61
8881370 1996

Variations for Indolent B Cell Lymphoma

Expression for Indolent B Cell Lymphoma

Search GEO for disease gene expression data for Indolent B Cell Lymphoma.

Pathways for Indolent B Cell Lymphoma

GO Terms for Indolent B Cell Lymphoma

Sources for Indolent B Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....